Focus: Bausch + Lomb is a specialty pharmaceutical and eye care company headquartered in Bridgewater, NJ, focused on ophthalmology with a diversified portfolio spanning prescription drugs, biologics, and ophthalmic devices.
Profile data last refreshed 21h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Bausch + Lomb to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Bausch + Lomb's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Blockbuster flagship with $473M Part D spending; represents 50% of company revenue and core earnings driver through 2033.
Help build intelligence for Bausch + Lomb
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Second-largest revenue contributor with $117M Part D spending; patent cliff in 2029 creates near-term margin headwind and restructuring catalyst.
NSAID anti-inflammatory generating $95M Part D spending; protected through 2033 with stable market position in post-operative care.
Azole antifungal with $94M Part D spending; longest exclusivity runway (2035) among top products, serving niche but stable fungal disease market.
Non-ophthalmology asset generating $77M Part D spending; LOE approaching but specific date unknown; signals portfolio diversification outside core indication.
ANDA generic with $28M Part D spending; post-LOE mature product with limited growth potential but stable base business.
Corticosteroid with $21M Part D spending; longest exclusivity window among smaller products (through 2036), serving inflammation indication.
Non-ophthalmology antidepressant with $20M Part D spending; already past or approaching LOE in 2026, contributing minimal to future earnings.
Ophthalmology corticosteroid with $11M Part D spending; LOE approaching in near-term, contributing minimally to sustainability.
179 discontinued, 67 duplicate formulations not shown
+28 more products with revenue data
Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data - Clinical Trials Arena
Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data Clinical Trials Arena
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies - finance.yahoo.com
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies finance.yahoo.com
Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail - BioSpace
Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail BioSpace
Bausch + Lomb advances 2 first-in-class eye health therapies - Optometry Times
Bausch + Lomb advances 2 first-in-class eye health therapies Optometry Times
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal - finance.yahoo.com
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal finance.yahoo.com
Bausch & Lomb Earnings: Momentum in Implantables and Pharmaceuticals Shows Off Investment Dividends - Morningstar
Bausch & Lomb Earnings: Momentum in Implantables and Pharmaceuticals Shows Off Investment Dividends Morningstar
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
+63 more products
Two WARN filings within 13 months totaling 449 jobs, combined with zero active hiring, indicate Bausch + Lomb is in financial distress management; individual contributor roles face elevated severance risk through 2026.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo